Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

458 questions · 473 findings · 205 reviews

No studies found 128 · 27.1%GRADE not reported 49 · 10.4%Very low 142 · 30%Low 106 · 22.4%Moderate 36 · 7.6%High 12 · 2.5%

Anti‐TNF discontinuation vs anti‐TNF continuation

Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF discontinuation showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (moderate certainty).

1 finding from 1 review

Anti‐TNF dose reduction vs anti‐TNF continuation

Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF dose reduction showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (low certainty).

1 finding from 1 review

Intervention not reported

Severe adverse events (≥ grade 3) · women withe low‐risk GTN

The intervention showed no clear difference in severe adverse events (≥ grade 3) (low certainty).

1 finding from 1 review

Serenoa repens vs placebo or no intervention

Adverse eventsCumulative incidence · men with lower urinary tract symptoms secondary to benign prostatic obstruction

Serenoa repens showed no clear difference in adverse eventsCumulative incidence compared with placebo or no intervention (moderate certainty).

1 finding from 1 review

Serenoa repens in combination with other phytotherapy vs placebo or no intervention

Adverse eventsCumulative incidence · men with lower urinary tract symptoms secondary to benign prostatic obstruction

Serenoa repens in combination with other phytotherapy showed no clear difference in adverse eventsCumulative incidence compared with placebo or no intervention (low certainty).

1 finding from 1 review

Paracetamol vs placebo

Any adverse events Up to 12 weeks' · Patients with acute low‐back pain

Paracetamol showed no clear difference in any adverse events Up to 12 weeks' compared with placebo (high certainty).

1 finding from 1 review

Timing of wound closure (immediate vs delayed)

Adverse events ‐ superficial infection · adults with open long bone fractures of the upper and lower limbs

It is very uncertain whether timing of wound closure (immediate changes adverse events ‐ superficial infection compared with delayed) (very low certainty).

1 finding from 1 review

Paracetamol vs placebo

Serious adverse events Up to 12 weeks' · Patients with acute low‐back pain

Paracetamol showed no clear difference in serious adverse events Up to 12 weeks' compared with placebo (moderate certainty).

1 finding from 1 review

Oral paracetamol vs placebo

Patients with one or more adverse events · Patients requiring surgical removal of a lower wisdom tooth or teeth, with baseline moderate to severe pain (surgery under local…

Paracetamol (single oral dose, any dose or formulation; subgroups up… showed no clear difference in patients with one or more adverse events compared with placebo; GRADE not reported.

1 finding from 1 review

Interdisciplinary enhanced rehabilitation (inpatient and community rehabilitation) vs conventional rehabilitation

Adverse effects (fall down) · adults with dementia following hip fracture surgery

It is very uncertain whether interdisciplinary enhanced rehabilitation (inpatient and community… changes adverse events (incidence of falls at 12 months) compared with conventional rehabilitation (very low certainty).

1 finding from 1 review

Geriatrician‐led inpatient management vs orthopaedic‐led inpatient management

Adverse events (delirium during hospitalisation) · adults with dementia following hip fracture surgery

It is very uncertain whether geriatrician‐led inpatient management changes adverse events (delirium during hospitalisation) compared with orthopaedic‐led inpatient management (very low certainty).

1 finding from 1 review

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Withdrawals due to adverse events not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

The review found no eligible studies for this question.

1 finding from 1 review